menu
    • menu
    [{"orgOrder":0,"company":"PHARMAZEUTISCHE FABRIK MONTAVIT","sponsor":"PHARMAZEUTISCHE FABRIK MONTAVIT","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Prof-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PHARMAZEUTISCHE FABRIK MONTAVIT","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"PHARMAZEUTISCHE FABRIK MONTAVIT \/ PHARMAZEUTISCHE FABRIK MONTAVIT","highestDevelopmentStatusID":"9","companyTruncated":"PHARMAZEUTISCHE FABRIK MONTAVIT \/ PHARMAZEUTISCHE FABRIK MONTAVIT"}]

    Find Clinical Drug Pipeline Developments & Deals by PHARMAZEUTISCHE FABRIK MONTAVIT

    Menu

    PHARMAZEUTISCHE FABRIK MONTAVIT

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PHARMAZEUTISCHE FABRIK MONTAVIT

                            Austria arrow
                            ACI Convention
                            Not Confirmed

                            PHARMAZEUTISCHE FABRIK MONTAVIT

                            Austria arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Prof-001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : ProFem GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)

                            Details : Prof-001 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Candidiasis, Vulvovaginal.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 02, 2021

                            Lead Product(s) : Prof-001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : ProFem GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth